255 related articles for article (PubMed ID: 31695022)
1. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
[TBL] [Abstract][Full Text] [Related]
2. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
6. MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA.
Yuan YL; Yu H; Mu SM; Dong YD; Li Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819851833. PubMed ID: 31570091
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
[TBL] [Abstract][Full Text] [Related]
11. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
[TBL] [Abstract][Full Text] [Related]
12. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract][Full Text] [Related]
13. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma.
Iwai N; Yasui K; Tomie A; Gen Y; Terasaki K; Kitaichi T; Soda T; Yamada N; Dohi O; Seko Y; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Konishi H; Naito Y; Itoh Y
Int J Oncol; 2018 Jul; 53(1):237-245. PubMed ID: 29658604
[TBL] [Abstract][Full Text] [Related]
15. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.
Cao MQ; You AB; Zhu XD; Zhang W; Zhang YY; Zhang SZ; Zhang KW; Cai H; Shi WK; Li XL; Li KS; Gao DM; Ma DN; Ye BG; Wang CH; Qin CD; Sun HC; Zhang T; Tang ZY
J Hematol Oncol; 2018 Jan; 11(1):12. PubMed ID: 29361949
[TBL] [Abstract][Full Text] [Related]
16. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis.
Qian F; Hu Q; Tian Y; Wu J; Li D; Tao M; Qin L; Shen B; Xie Y
Int J Biol Sci; 2019; 15(2):369-385. PubMed ID: 30745827
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
[TBL] [Abstract][Full Text] [Related]
19. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
Lou G; Song X; Yang F; Wu S; Wang J; Chen Z; Liu Y
J Hematol Oncol; 2015 Oct; 8():122. PubMed ID: 26514126
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.
Zhang Y; Tie Q; Bao Z; Shao Z; Zhang L
Comput Math Methods Med; 2021; 2021():6468405. PubMed ID: 34812269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
